(Q33771058)

29 July 2017

1 reference

title

Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy (English)

1 reference

29 July 2017

1 reference

1 reference

E A Lew

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

Alimentary Pharmacology & Therapeutics

29 July 2017

published in

1 reference

29 July 2017

volume

13 Suppl 5

1 reference

29 July 2017

page(s)

11-16

1 reference

Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Clinical pharmacology of omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Clinical importance of hepatic cytochrome P450 in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00034.X

10.1046/J.1365-2036.1999.00034.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference